Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs EHang Holdings Ltd - ADR (EH) Price & Performance

Amphastar Pharmaceuticals IncTrade
EHang Holdings Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs EHang Holdings Ltd - ADR — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.91 (market cap $868.62M), while EHang Holdings Ltd - ADR trades at $5.66 (market cap $437.63M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.

AMPHEH
Market Cap
$868.62M$437.63M
Sector
HealthIndustrials
52-Week High
$30.81$19.44
52-Week Low
$16.87$4.90
Enterprise Value
$1.27B$376.84M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.79, up 1.76% today, with a mixed technical signal (bullish overall, bearish moving averages). The company reported Q1 2026 revenue of $418M, flat year-over-year, but net income margin remains deeply negative at -77.56%. Recent news includes the EH216-S completing Central Asia's first pilotless eVTOL flight in Kazakhstan (GlobeNewsWire, August 10, 2026), highlighting operational progress amid financial challenges.

Outlook is cautious; the stock faces significant execution risk with persistent losses and high cash burn, but analyst consensus price target of $6.97 offers modest upside. Investment opportunity hinges on successful commercialization of eVTOL technology, while risks include intense competition, regulatory hurdles, and reliance on financing to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH